Risankizumab for the treatment of genital psoriasis: A 1-year, real-world experience.
作者信息
Orsini D, Frascione P, Assorgi C, Pacifico A, Sperduti I, Gargiulo L, Ibba L, Valenti M, Costanzo A, Narcisi A
机构信息
Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
Dermatology Oncology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.
出版信息
J Eur Acad Dermatol Venereol. 2024 Mar;38(3):e256-e258. doi: 10.1111/jdv.19562. Epub 2023 Oct 17.
PMID:37795669
Abstract
摘要
相似文献
1
Risankizumab for the treatment of genital psoriasis: A 1-year, real-world experience.瑞莎珠单抗治疗生殖器银屑病：1年的真实世界经验。
J Eur Acad Dermatol Venereol. 2024 Mar;38(3):e256-e258. doi: 10.1111/jdv.19562. Epub 2023 Oct 17.
2
A head-to-head comparison of risankizumab and ixekizumab for genital psoriasis: a real-life, 24-week, prospective study.司库奇尤单抗与依奇珠单抗治疗生殖器银屑病的头对头比较：一项为期24周的真实世界前瞻性研究。
J Eur Acad Dermatol Venereol. 2022 May;36(5):e359-e361. doi: 10.1111/jdv.17880. Epub 2021 Dec 31.
3
Exclusively genital psoriasis successfully treated with Risankizumab.仅累及生殖器的银屑病经司库奇尤单抗治疗成功。
Dermatol Ther. 2022 Aug;35(8):e15591. doi: 10.1111/dth.15591. Epub 2022 Jun 6.
4
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers.利纳西珠单抗治疗难治性部位斑块状银屑病的疗效：来自两个转诊中心的真实世界经验。
J Dermatolog Treat. 2023 Dec;34(1):2220849. doi: 10.1080/09546634.2023.2220849.
5
Real-world experience with risankizumab in patients with plaque psoriasis: a retrospective study.司库奇尤单抗治疗斑块状银屑病患者的真实世界经验：一项回顾性研究。
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e685-e688. doi: 10.1111/jdv.17410. Epub 2021 Jun 25.
6
Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.意大利一项回顾性研究显示，古塞库单抗与里沙鲁单抗在真实世界实践中的间接比较结果。
Dermatol Ther. 2022 Jan;35(1):e15214. doi: 10.1111/dth.15214. Epub 2021 Nov 30.
7
Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.意大利一项为期 28 周的回顾性研究：真实世界中古塞库单抗、里莎鲁单抗和替西珠单抗的间接比较。
J Dermatolog Treat. 2022 Sep;33(6):2813-2820. doi: 10.1080/09546634.2022.2081655. Epub 2022 May 29.
8
Effectiveness and safety of reduced-dose secukinumab switching to risankizumab for psoriasis patients in Asian population: A case series.亚洲人群中银屑病患者从低剂量司库奇尤单抗转换为瑞莎珠单抗的有效性和安全性：病例系列
Exp Dermatol. 2023 Jul;32(7):1048-1050. doi: 10.1111/exd.14810. Epub 2023 Apr 9.
9
Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.利纳西珠单抗治疗中重度银屑病：一项多中心、回顾性、1 年真实世界研究。
Dermatol Ther. 2022 Jun;35(6):e15489. doi: 10.1111/dth.15489. Epub 2022 Apr 13.
10
Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison.古塞库单抗和司库奇尤单抗治疗银屑病：44周间接真实世界比较
J Am Acad Dermatol. 2021 Oct;85(4):1028-1030. doi: 10.1016/j.jaad.2021.01.025. Epub 2021 Mar 21.
引用本文的文献
1
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus.真实世界临床实践中使用JAK抑制剂治疗中重度特应性皮炎患者：意大利德尔菲共识
Dermatol Ther (Heidelb). 2024 Apr;14(4):919-932. doi: 10.1007/s13555-024-01135-x. Epub 2024 Mar 21.
2
Effectiveness of ixekizumab for the treatment of moderate-to-severe plaque psoriasis with involvement of difficult-to-treat areas: A 52-week multicenter retrospective study.依奇珠单抗治疗中重度斑块型银屑病（累及难治疗部位）的疗效：一项 52 周多中心回顾性研究。
J Dermatol. 2024 Jun;51(6):839-843. doi: 10.1111/1346-8138.17115. Epub 2024 Jan 31.
3
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS).司库奇尤单抗在真实世界环境中的有效性、耐受性和药物留存率：一项为期三年的回顾性多中心研究-IL PSO（意大利银屑病概况）
J Clin Med. 2024 Jan 16;13(2):495. doi: 10.3390/jcm13020495.
Zotero 插件